These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23575267)

  • 1. Treatment of children with high grade glioma with nimotuzumab: a 5-year institutional experience.
    Cabanas R; Saurez G; Rios M; Alert J; Reyes A; Valdes J; Gonzalez MC; Pedrayes JL; Avila M; Herrera R; Infante M; Echevarria E; Moreno M; Luaces PL; Ramos TC
    MAbs; 2013; 5(2):202-7. PubMed ID: 23575267
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nimotuzumab in combination with radiotherapy in high grade glioma patients: a single institution experience.
    Solomon MT; Miranda N; Jorrín E; Chon I; Marinello JJ; Alert J; Lorenzo-Luaces P; Crombet T
    Cancer Biol Ther; 2014 May; 15(5):504-9. PubMed ID: 24521695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.
    Solomón MT; Selva JC; Figueredo J; Vaquer J; Toledo C; Quintanal N; Salva S; Domíngez R; Alert J; Marinello JJ; Catalá M; Griego MG; Martell JA; Luaces PL; Ballesteros J; de-Castro N; Bach F; Crombet T
    BMC Cancer; 2013 Jun; 13():299. PubMed ID: 23782513
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged use of nimotuzumab in children with central nervous system tumors: safety and feasibility.
    Cabanas R; Saurez G; Alert J; Reyes A; Valdes J; Gonzalez MC; Pedrayes JL; Valle L; Infante M; Avila M; Herrera R; Hechavarria E; Rios M; Fernández A; Lorenzo Luaces P; Crombet Ramos T
    Cancer Biother Radiopharm; 2014 May; 29(4):173-8. PubMed ID: 24784755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a phase I/II trial.
    Ramos TC; Figueredo J; Catala M; González S; Selva JC; Cruz TM; Toledo C; Silva S; Pestano Y; Ramos M; Leonard I; Torres O; Marinello P; Pérez R; Lage A
    Cancer Biol Ther; 2006 Apr; 5(4):375-9. PubMed ID: 16575203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Malignant astrocytic gliomas in children.
    Marchese MJ; Chang CH
    Cancer; 1990 Jun; 65(12):2771-8. PubMed ID: 2160318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nimotuzumab as Additional Therapy for GLIOMA in Pediatric and Adolescent: A Systematic Review.
    Parenrengi MA; Suryaningtyas W; Al Fauzi A; Hafid Bajamal A; Kusumastuti K; Utomo B; Muslim Hidayat Thamrin A; Sulistiono B
    Cancer Control; 2022; 29():10732748211053927. PubMed ID: 35191733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nimotuzumab-containing regimen for pediatric diffuse intrinsic pontine gliomas: a retrospective multicenter study and review of the literature.
    Kebudi R; Cakir FB; Bay SB; Gorgun O; Altınok P; Iribas A; Agaoglu FY; Darendeliler E
    Childs Nerv Syst; 2019 Jan; 35(1):83-89. PubMed ID: 30417211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 2 study of safety and efficacy of nimotuzumab in pediatric patients with progressive diffuse intrinsic pontine glioma.
    Bartels U; Wolff J; Gore L; Dunkel I; Gilheeney S; Allen J; Goldman S; Yalon M; Packer RJ; Korones DN; Smith A; Cohen K; Kuttesch J; Strother D; Baruchel S; Gammon J; Kowalski M; Bouffet E
    Neuro Oncol; 2014 Nov; 16(11):1554-9. PubMed ID: 24847085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of high-grade glioma in children and adolescents.
    MacDonald TJ; Aguilera D; Kramm CM
    Neuro Oncol; 2011 Oct; 13(10):1049-58. PubMed ID: 21784756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of nimotuzumab in the treatment of high-grade glioma.
    Yang QY; Guo CC; Chen ZP
    Onco Targets Ther; 2015; 8():819-25. PubMed ID: 25926743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment modalities for malignant gliomas with reference to their pathophysiology].
    Kobayashi S; Takakura K
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):11-7. PubMed ID: 3942392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of the multicenter, multidisciplinary treatment study HIT-LGG-1996 for low-grade glioma in children and adolescents of the German Speaking Society of Pediatric Oncology and Hematology.
    Gnekow AK; Falkenstein F; von Hornstein S; Zwiener I; Berkefeld S; Bison B; Warmuth-Metz M; Driever PH; Soerensen N; Kortmann RD; Pietsch T; Faldum A
    Neuro Oncol; 2012 Oct; 14(10):1265-84. PubMed ID: 22942186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Nimotuzumab in combination with chemotherapy for patients with malignant gliomas].
    Yang QY; Shen D; Sai K; Mu YG; Jiang XB; Zhang XH; Chen ZP
    Zhonghua Zhong Liu Za Zhi; 2011 Mar; 33(3):232-5. PubMed ID: 21575527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current knowledge and treatment strategies for grade II gliomas.
    Narita Y
    Neurol Med Chir (Tokyo); 2013; 53(7):429-37. PubMed ID: 23883553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of nimotuzumab and vinorelbine, radiation and re-irradiation for diffuse pontine glioma in childhood.
    Massimino M; Biassoni V; Miceli R; Schiavello E; Warmuth-Metz M; Modena P; Casanova M; Pecori E; Giangaspero F; Antonelli M; Buttarelli FR; Potepan P; Pollo B; Nunziata R; Spreafico F; Podda M; Anichini A; Clerici CA; Sardi I; De Cecco L; Bode U; Bach F; Gandola L
    J Neurooncol; 2014 Jun; 118(2):305-312. PubMed ID: 24696052
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.
    Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; Cokgor I; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Regalado LV; Sampson JH; Shafman TD; Wikstrand CJ; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
    J Clin Oncol; 2002 Mar; 20(5):1389-97. PubMed ID: 11870184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spectrum of pediatric gliomas: implications for the development of future therapies.
    Pytel P
    Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S51-60. PubMed ID: 18076319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant EGFR in vivo.
    Nitta Y; Shimizu S; Shishido-Hara Y; Suzuki K; Shiokawa Y; Nagane M
    Cancer Med; 2016 Mar; 5(3):486-99. PubMed ID: 26778701
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.